10:59 EDT Corcept Therapeutics (CORT) up 43% to $48.35 after FDA approves Lifyorli
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- FDA approves Corcept Therapeutics’ Lifyorli for certain cancers
- Corcept Therapeutics jump 10% after FDA approves Lifyorli cancer treatment
- Corcept Therapeutics trading halted, volatility trading pause
- Corcept Therapeutics management to meet with Piper Sandler
- Corcept Therapeutics director buys $3.3M in common stock